Novoprotein Scientific EBITDA TCAC 3A

Que fait Novoprotein Scientific ? Novoprotein Scientific Inc generates revenue through the development, production, and sale of recombinant protein solutions. The company offers target and factor proteins, recombinant antibodies, enzymes, and reagents, along with technical services. Its main products include novel coronavirus diagnostic antibodies, antigens, pseudoviruses, non-structural proteins, and mRNA raw material enzymes and reagents. These products are primarily sold to customers in biological medicine, life science research, in vitro diagnostics, and mRNA vaccine drug sectors. The firm serves both domestic and international markets with its comprehensive portfolio of protein-based solutions. The company's revenue streams are derived from the sale of specialized biological reagents and technical services. Customers in the pharmaceutical and biotechnology industries purchase these products for research and diagnostic applications. The firm's focus on novel coronavirus-related products positions it within the healthcare and vaccine development markets. Novoprotein Scientific Inc targets both domestic Chinese and overseas markets for its protein application solutions. Novoprotein Scientific Inc's business model centers on providing high-value recombinant protein products and services for the life science and healthcare sectors. The company's product portfolio includes diagnostic tools for viral detection and mRNA vaccine components. These offerings are tailored to meet the needs of research institutions, diagnostic laboratories, and pharmaceutical companies. The firm's technical services support customers in developing and implementing protein-based solutions across multiple applications. Novoprotein Scientific est l'une des entreprises les plus populaires sur Eulerpool.